

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	2
METHODOLOGIES AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED BCC REPORTS	2
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASE</i> <i>TREATMENTS, THROUGH 2014 (\$ BILLIONS)</i>	 5
<i>SUMMARY FIGURE GLOBAL MARKET FOR INFECTIOUS DISEASE</i> <i>TREATMENTS, 2008-2014 (\$ BILLIONS)</i>	 5
 CHAPTER THREE: OVERVIEW	 6
<i>TABLE 1 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE,</i> <i>2006 (NUMBER OF CASES, ANNUALLY)</i>	 6
<i>TABLE 1 (CONTINUED)</i>	7
HISTORICAL IMPACT OF INFECTIOUS DISEASES.....	7
LINKING INFECTIOUS DISEASE TO CANCER.....	8
TRANSMISSION OF INFECTIOUS DISEASES.....	8
TREATMENTS FOR INFECTIOUS DISEASES	8
PREVENTION.....	8
VACCINATION.....	9
<i>FIGURE 1 PERCENT OF PREVENTABLE CHILDHOOD DEATHS</i> <i>WITH VACCINATION, 2002 (%)</i>	 9
<i>FIGURE 1 (CONTINUED)</i>	10
<i>TABLE 2 MAJOR MANUFACTURERS OF VACCINES FOR</i> <i>INFECTIOUS DISEASES, 2008</i>	 10
<i>TABLE 3 ESTIMATED VACCINE SALES FOR INFECTIOUS</i> <i>DISEASES, BY MANUFACTURER, 2008 (%/\$ MILLIONS)</i>	 11
<i>TABLE 4 PROJECTED SALES OF VACCINES TO TREAT</i> <i>INFECTIOUS DISEASES WORLDWIDE, THROUGH 2014 (\$</i> <i>BILLIONS)</i>	 12
<i>TABLE 5 SELECTED TREATMENT MODALITIES, BY DISEASE AND</i> <i>TYPE OF PRODUCT</i>	 12
MONITORING AND SURVEILLANCE	13
CURRENT IMPACT OF INFECTIOUS DISEASES.....	13
<i>TABLE 6 TOP 10 CAUSES OF DEATH, BY INCOME GROUP, 2004 (%)</i>	13
<i>TABLE 6 (CONTINUED)</i>	14
ANTIBIOTIC-RESISTANT ORGANISMS.....	14

IMPLICATIONS OF CLIMATE-CHANGE ON INFECTIOUS DISEASES.....	14
KEY DRIVERS OF INFECTIOUS DISEASE PRODUCT MARKET.....	15
KEY OBSTACLES IN THE INFECTIOUS DISEASE PRODUCT MARKET.....	15
OPPORTUNITIES TO FIGHT INFECTIOUS DISEASES.....	16
OPPORTUNITIES TO FIGHT ... (CONTINUED).....	17
 CHAPTER FOUR: THE GLOBAL STATE OF INFECTIOUS DISEASE	
CONTROL AND TREATMENT	18
FACTORS IN THE EMERGENCE OF INFECTIONS	18
HUMAN DEMOGRAPHICS AND BEHAVIOR	18
TECHNOLOGY.....	18
ECONOMIC DEVELOPMENT AND LAND USE.....	19
INTERNATIONAL TRAVEL.....	19
MICROBIAL ADAPTATION	19
<i>TABLE 7 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL</i>	20
PUBLIC HEALTH MEASURES	20
GLOBAL IMPLICATIONS OF INFECTIOUS DISEASES	20
REGIONAL TRENDS	21
Sub-Saharan Africa	21
Asia and the Pacific	21
The Former Soviet Union and Eastern Europe.....	21
Latin America	21
Middle East and North Africa.....	21
Western Europe	22
GLOBAL ECONOMIC, SOCIAL, AND POLITICAL IMPACT.....	22
ECONOMIC COSTS	22
SOCIAL COSTS	23
POLITICAL IMPACT.....	23
IMPLICATIONS OF INFECTIOUS DISEASE IN THE U.S.....	23
HIV/AIDS.....	23
HEPATITIS C.....	24
TUBERCULOSIS.....	24
INFLUENZA	24
ANTIBIOTIC-RESISTANT PATHOGENS	24
FOOD-BORNE ILLNESSES	24
INFECTIOUS DISEASES ACQUIRED OUTSIDE OF THE U.S.....	25
EMERGING INFECTIOUS DISEASES	25
EMERGING BACTERIAL INFECTIOUS DISEASES.....	25
EMERGING VIRAL INFECTIOUS DISEASES.....	25
Metapneumoviruses	26
Henipavirus—Nipah, Hendra	26
PRION DISEASE	26
CREATING TREATMENTS FOR INFECTIOUS DISEASE.....	27

CREATING DRUG TREATMENTS.....	27
<i>TABLE 8 PROCESS OF CREATING DRUG TREATMENTS</i>	27
<i>TABLE 8 (CONTINUED)</i>	28
CREATING VACCINES	29
Creating Vaccines (Continued)	30
<i>TABLE 9 TOP FIVE VACCINE-PRODUCING COMPANIES, 2009</i>	31
ACQUISITIONS AMONG MANUFACTURERS OF INFECTIOUS DISEASE PRODUCTS.....	31
<i>TABLE 10 SELECTED ACQUISITIONS AMONG INFECTIOUS DISEASE DRUG AND VACCINE MANUFACTURERS, 2006-2010</i>	31
<i>TABLE 10 (CONTINUED)</i>	32
CHAPTER FIVE: BACTERIAL INFECTIOUS DISEASES	33
<i>TABLE 11 SELECTED BACTERIAL INFECTIOUS DISEASES AND THE NUMBER OF CASES IN HUMANS</i>	33
<i>TABLE 11 (CONTINUED)</i>	34
<i>TABLE 12 PROJECTED MARKET FOR ANTIBACTERIAL TREATMENTS THROUGH 2014 (\$ MILLIONS)</i>	34
THE GLOBAL ANTIBACTERIAL DRUG MARKET.....	35
TREATMENTS	35
<i>FIGURE 2 LEADING MANUFACTURERS OF ANTIBACTERIAL DRUGS, WITH APPROXIMATE MARKET SHARE, 2008 (%)</i>	35
<i>FIGURE 2 (CONTINUED)</i>	36
<i>TABLE 13 MAJOR MANUFACTURERS OF ANTIBACTERIALS AND THEIR PRODUCTS, 2009</i>	36
MAJOR INFECTIOUS BACTERIAL DISEASES	37
BACTERIAL DIARRHEAL DISEASES.....	37
Cholera	37
Frequency	37
Treatment.....	38
<i>Clostridium Difficile</i>	38
Treatments under Development	38
<i>Campylobacter</i>	39
Treatment.....	39
EMERGING FOOD-BORNE/WATER-BORNE ILLNESSES	39
<i>TABLE 14 CURRENTLY AVAILABLE TREATMENTS FOR SALMONELLA AND THEIR MANUFACTURERS</i>	40
<i>HAEMOPHILUS INFLUENZAE B (HIB)</i>	41
Vaccination	41
<i>TABLE 15 PROJECTED MARKET FOR HIB VACCINE, THROUGH 2014 (\$ MILLIONS)</i>	42
PNEUMONIA.....	42
Current Treatment.....	42
Vaccines	42

<i>TABLE 16 PROJECTED REVENUES FROM VACCINES AND MEDICATIONS TO TREAT PNEUMONIA, THROUGH 2014 (\$ MILLIONS)</i>	43
SEXUALLY TRANSMITTED DISEASES	43
Chlamydia.....	43
<i>TABLE 17 PRIMARY ANTIBIOTICS TO TREAT CHLAMYDIA</i>	44
Emerging Treatment	44
Gonorrhea	44
<i>TABLE 18 PRIMARY ANTIBIOTICS TO TREAT GONORRHEA</i>	45
Emerging Treatment	45
Syphilis.....	45
Chancroid.....	46
STAPHYLOCOCCAL INFECTIONS	46
Emerging Treatments	47
Dalbavancin	47
Telavancin	47
Oritavancin	47
Ceftobiprole	48
Ceftaroline.....	48
TUBERCULOSIS	48
<i>TABLE 19 NUMBER OF CASES OF TB ANNUALLY, BY COUNTRY, 2007</i>	49
Frequency.....	49
United States	49
European Region.....	50
Drug-resistant Strains	50
Current Treatments	50
<i>TABLE 20 PROJECTED GLOBAL REVENUES FOR TB DRUGS, THROUGH 2014 (\$ MILLIONS)</i>	51
<i>TABLE 21 CURRENTLY AVAILABLE TREATMENTS FOR TB AND THEIR MANUFACTURERS</i>	51
Emerging Treatments	51
URINARY TRACT INFECTIONS.....	52
<i>TABLE 22 CURRENTLY AVAILABLE TREATMENTS FOR UTIS AND THEIR MANUFACTURERS</i>	53
EMERGING TREATMENTS.....	53
Bacterial Interference.....	53
Bacteriophage Therapy	53
Bacteriophage Therapy (Continued)	54
Bacterial Vaccines	55
Cationic Peptides	55
Cyclic D,L-a-Peptides.....	56
CHAPTER SIX: FUNGAL INFECTIOUS DISEASES.....	57
OPPORTUNISTIC FUNGAL INFECTIONS.....	57

PRIMARY FUNGAL INFECTIONS	57
FUNGAL INFECTIOUS DISEASES	58
<i>TABLE 23 PROJECTED COST OF ANTIFUNGAL AGENTS TO TREAT FUNGAL INFECTIONS, THROUGH 2014 (\$ BILLIONS)</i>	58
<i>FIGURE 3 MARKET SHARE OF COMPANIES INVOLVED IN THE TREATMENT OF FUNGAL INFECTIONS, 2009 (%)</i>	59
CANDIDIASIS.....	59
Causes of Candidiasis.....	60
Frequency.....	60
Treatment	61
<i>TABLE 24 CURRENT MEDICATIONS FOR CANDIDIASIS, 2009</i>	61
<i>TABLE 24 (CONTINUED)</i>	62
Future Market	62
ASPERGILLOSIS.....	62
<i>TABLE 25 CURRENT MEDICATIONS FOR ASPERGILLOSIS, 2009</i>	63
COCCIDIOIDOMYCOSIS	63
Frequency.....	63
Treatment	64
<i>TABLE 26 CURRENT MEDICATIONS FOR COCCIDIODOMYCOSIS, 2009</i>	64
CRYPTOCOCCOSIS	64
Frequency.....	65
Treatment	65
<i>TABLE 27 CURRENT MEDICATIONS FOR CRYPTOCOCCOSIS, 2009</i>	65
MUCORMYCOSIS	65
Frequency.....	66
Treatment	66
<i>TABLE 28 CURRENT MEDICATIONS FOR MUCORMYCOSIS, 2009</i>	66
PARACOCCIDIOIDOMYCOSIS	67
Frequency.....	67
Treatment	67
<i>TABLE 29 CURRENT MEDICATIONS FOR PARACOCCIDIOIDOMYCOSIS, 2009</i>	67
PNEUMOCYSTIS CARINII	68
Frequency.....	68
Treatment	68
<i>TABLE 30 CURRENT MEDICATIONS FOR PNEUMOCYSTIS CARNII, 2009</i>	69
SPOROTYRICHOSIS.....	69
Treatment	69
<i>TABLE 31 CURRENT MEDICATIONS FOR SPOROTYRICHOSIS, 2009</i>	69
TRICHOSPORON INFECTIONS.....	70
Frequency.....	70
Treatment	70

<i>TABLE 32 CURRENT MEDICATIONS FOR TRICHOSPORON INFECTIONS, 2009</i>	70
ZYGOMYCOSIS	71
Frequency.....	71
Treatment	71
<i>TABLE 33 CURRENT MEDICATIONS FOR ZYGOMYCOSIS, 2009</i>	71
CHAPTER SEVEN: VIRAL INFECTIOUS DISEASE	72
MAJOR DISEASES	72
RESEARCH FUNDING.....	72
<i>TABLE 34 GLOBAL PROJECTIONS FOR VIRAL INFECTIOUS DISEASE TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	73
HIV/AIDS	73
<i>TABLE 35 PROJECTED GLOBAL MARKET FOR HIV DRUGS, THROUGH 2014 (\$ MILLIONS)</i>	74
SHIFTING PRIORITIES	74
<i>TABLE 36 10 LEADING GLOBAL HIV MANUFACTURERS, 2010</i>	74
<i>FIGURE 4 MARKET SHARE FOR TOP MANUFACTURERS OF HIV TREATMENTS, 2009 (%)</i>	75
EMERGING TREATMENTS.....	76
Gilead Sciences	76
Merck	76
ViiV Healthcare	76
Tibotec.....	76
TMC 278	77
COMMON PEDIATRIC VIRAL INFECTIONS.....	77
POLIOMYELITIS	77
DIPHTHERIA, TETANUS, PERTUSSIS (DTP).....	78
<i>TABLE 37 PROJECTIONS FOR DTP, POLIO, HIB COMBINATION VACCINE SALES, THROUGH 2014 (\$ MILLIONS)</i>	79
MEASLES, MUMPS, RUBELLA	79
Measles.....	79
Mumps.....	80
Rubella	80
<i>TABLE 38 PROJECTED GLOBAL REVENUES FROM MMR VACCINE, THROUGH 2014 (\$ MILLIONS)</i>	81
CROUP	81
OTITIS MEDIA (EAR INFECTIONS)	81
Causes of Otitis Media	82
Treatment	82
<i>TABLE 39 PROJECTED COSTS OF OTITIS MEDIA TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	82
Pharmacological Intervention.....	82
Surgical Intervention	83

<i>TABLE 40 GLOBAL SURGICAL COSTS FOR MYRINGOTOMY IN PEDIATRIC PATIENTS, THROUGH 2014 (\$ MILLIONS)</i>	83
<i>TABLE 41 GLOBAL SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN PEDIATRIC PATIENTS, THROUGH 2014 (\$ MILLIONS)</i>	84
INFLUENZA	84
INFLUENZA TREATMENTS	85
<i>TABLE 42 PROJECTED GLOBAL MARKET FOR INFLUENZA TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	85
<i>FIGURE 5 ESTIMATED MARKET SHARE OF COMPANIES IN INFLUENZA TREATMENT MARKET, 2009 (%)</i>	86
EMERGING TREATMENTS	86
HEPATITIS	87
<i>TABLE 43 HEPATITIS CHARACTERISTICS, BY TYPE</i>	87
<i>TABLE 43 (CONTINUED)</i>	88
<i>TABLE 44 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2010</i>	88
<i>TABLE 44 (CONTINUED)</i>	89
<i>TABLE 45 PROJECTED MARKET FOR HEPATITIS MEDICATIONS AND VACCINES, THROUGH 2014 (\$ MILLIONS)</i>	90
HEPATITIS A.....	90
<i>TABLE 46 PROJECTED REVENUE FROM HEPATITIS A VACCINATION AND TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	91
HEPATITIS B.....	91
<i>TABLE 47 PROJECTED REVENUE FROM HEPATITIS B VACCINATION AND TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	92
Emerging Treatments	92
HEPATITIS C.....	92
<i>TABLE 48 PROJECTED REVENUE FROM HEPATITIS C TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	93
<i>FIGURE 6 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%)</i>	93
<i>FIGURE 6 (CONTINUED)</i>	94
Emerging Treatments	94
HERPES VIRUSES	94
<i>TABLE 49 HERPES VIRUSES THAT INFECT HUMANS</i>	94
<i>TABLE 50 PROJECTED MARKET FOR HERPES SIMPLEX VIRUS MEDICATIONS, THROUGH 2014 (\$ MILLIONS)</i>	95
HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)	95
HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)	95
Prevalence.....	96
Emerging Treatment	96

Chiron.....	96
GlaxoSmithKline.....	97
Xenova/GlaxoSmithKline	97
Avant Immunotherapeutics.....	97
EPSTEIN-BARR VIRUS.....	98
HUMAN HERPES VIRUS 6.....	98
HUMAN HERPES VIRUS 8.....	98
EMERGING HERPES TREATMENTS	98
NanoViricides, Inc.	98
Cytogenix	99
Alnylam Pharmaceuticals, Inc.	99
VARICELLA VIRUSES	99
CHICKENPOX.....	99
SHINGLES	100
<i>TABLE 51 PROJECTED MARKET FOR VARICELLA VACCINES,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>101</i>
ENTEROVIRUSES	101
COXSACKIE VIRUSES	101
CREUTZFELDT-JAKOB DISEASE (CJD).....	102
EMERGING TREATMENTS.....	102
Quinacrine	102
Pentosan Polysulphate (PPS).....	103
OPPORTUNISTIC VIRAL INFECTIONS.....	103
CYTOMEGALOVIRUS	103
Current Treatments	104
<i>TABLE 52 CURRENT TREATMENT OPTIONS FOR CMV, 2009</i>	<i>104</i>
KAPOS'S SARCOMA (KS)	104
HEMORRHAGIC FEVERS	105
ARENAVIRUSES.....	106
BUNYAVIRUSES.....	106
FILOVIRUSES.....	106
FLAVIVIRUSES.....	107
Frequency.....	107
Current Treatment.....	108
HUMAN PAPILLOMAVIRUS (HPV)	108
TREATMENT.....	108
<i>TABLE 53 PROJECTED MARKET FOR HPV TREATMENTS,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>109</i>
EMERGING TREATMENTS.....	109
UPPER RESPIRATORY VIRUSES	109
COMMON COLD	109
SINUSITIS	110
RESPIRATORY SYNCYTIAL VIRUS (RSV).....	110
<i>TABLE 54 CURRENT TREATMENTS FOR RSV.....</i>	<i>111</i>

<i>TABLE 55 PROJECTED MARKET FOR RSV TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	111
Emerging Treatments	112
Arrow Therapeutics	112
Alnylam Pharmaceuticals	112
AstraZeneca/MedImmune	112
ROTAVIRUS	113
GLOBAL IMPACT	114
TREATMENTS.....	114
ROTATEQ.....	114
ROTARIX.....	114
<i>TABLE 56 GLOBAL REVENUES FOR PEDIATRIC ROTAVIRUS VACCINES, THROUGH 2014 (\$ MILLIONS)</i>	115
<i>TABLE 57 GLOBAL ROTAVIRUS VACCINE SALES, BY MANUFACTURER, 2008 (\$ MILLIONS/%)</i>	115
CHAPTER EIGHT: PARASITIC INFECTIOUS DISEASE.....	116
CAUSES OF PARASITIC DISEASE	116
MALARIA.....	116
<i>TABLE 58 PROJECTED GLOBAL REVENUES FOR MALARIAL PREVENTION AND TREATMENT MEASURES, THROUGH 2014 (\$ MILLIONS)</i>	117
CAUSES OF MALARIA.....	118
MALARIAL TREATMENTS.....	118
<i>TABLE 59 AVAILABLE DRUGS FOR THE TREATMENT OF MALARIA, 2009</i>	118
Current Treatments	119
<i>TABLE 60 PROJECTED GLOBAL REVENUE FROM MALARIAL TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	119
Evolving Treatments	119
GlaxoSmithKline.....	120
Novartis	120
Pfizer	120
Sanofi-aventis	120
Sigma-Tau	120
MOSQUITO NETTING.....	120
<i>TABLE 61 MOSQUITO NETTING DISTRIBUTED, 2006-2008</i>	121
<i>TABLE 62 PROJECTED SALES OF MOSQUITO NETTING TO GLOBAL RELIEF AGENCIES, THROUGH 2014 (\$ MILLIONS)</i>	121
NEGLECTED TROPICAL DISEASES	122
<i>TABLE 63 NUMBER OF ANNUAL INFECTIONS FROM LEISHMANIASIS, ONOCHOCERCIASIS, AND SCHISTOMIASIS</i>	122
<i>TABLE 64 AVAILABLE TREATMENTS FOR THE MOST COMMON NEGLECTED TROPICAL DISEASES</i>	123
LEISHMANIASIS	123

Current Treatment.....	124
Emerging Treatments	124
ONCHOCERCIASIS.....	124
Treatment	125
SCHISTOMIASIS.....	125
Treatment	126
TRYPANOSOMIASIS	127
African Trypanosomiasis.....	127
Chagas Disease.....	127
TREATMENT	127
EVOLVING TREATMENTS.....	128
<i>TABLE 65 AVAILABLE DRUGS FOR THE TREATMENT OF</i>	
<i>TRYPANOSOMIASIS, 2009.....</i>	<i>129</i>
LYMPHATIC FILIARIASIS	129
Treatment	130
DENGUE.....	130
OPPORTUNITIES FOR TREATMENTS FOR PARASITIC	
INFECTIOUS DISEASES.....	130
MALARIA	130
Synthetic Artemisinin	131
Eurartesim.....	131
Coartem Pediatric Dispersible Tablet	132
Pyramax.....	132
Phase I Projects	132
Tafenoquine.....	132
Artemisone.....	133
Preclinical Investigations.....	133
OZ 439	133
MK 4815	134
Mirincamycin	134
DENGUE.....	134
Clone Technology.....	135
Nucleotide Deletion	135
Other Approaches.....	136
SCHISTOSOMIASIS.....	136
ONCHOCERCIASIS	136
CHAPTER NINE: PATENT ANALYSIS	137
PATENT ANALYSIS	137
<i>TABLE 66 INFECTIOUS DISEASE TREATMENT PATENTS, BY</i>	
<i>COMPANY, YEAR FILED, AND DISEASE, 2000-2010.....</i>	<i>138</i>
<i>TABLE 66 (CONTINUED).....</i>	<i>139</i>
<i>TABLE 66 (CONTINUED).....</i>	<i>140</i>
<i>TABLE 66 (CONTINUED).....</i>	<i>141</i>

<i>TABLE 67 INFECTIOUS DISEASE TREATMENT PATENTS ISSUED BETWEEN JANUARY 2000 AND JANUARY 2010, BY MAJOR COMPANY</i>	142
<i>TABLE 68 INFECTIOUS DISEASE TREATMENT PATENTS, BY COUNTRY, 2000-2010</i>	143
<i>TABLE 69 PATENTS ISSUED FOR TREATMENT OF BACTERIAL DISEASE, 2000-2010</i>	143
<i>TABLE 70 PATENTS ISSUED FOR TREATMENT OF FUNGAL DISEASE, JANUARY 2000-JANUARY 2010</i>	144
<i>TABLE 71 PATENTS ISSUED FOR TREATMENT OF VIRAL DISEASE, JANUARY 2000-JANUARY 2010</i>	144
<i>TABLE 72 PATENTS ISSUED FOR TREATMENT OF PARASITIC DISEASE, JANUARY 2000- JANUARY 2010</i>	145
CHAPTER TEN: COMPANY DIRECTORY	146
AMYRIS BIOTECHNOLOGIES	146
BUSINESS OVERVIEW.....	146
ALNYLAM PHARMACEUTICALS	146
BUSINESS OVERVIEW.....	146
FINANCIALS	147
PRODUCTS	147
AR SCIENTIFIC	147
BUSINESS OVERVIEW.....	147
FINANCIALS	147
PRODUCTS	148
ASTRAZENECA.....	148
BUSINESS OVERVIEW.....	148
FINANCIALS	148
PRODUCTS	149
BAXTER INTERNATIONAL, INC.	149
BUSINESS OVERVIEW.....	149
FINANCIALS	149
PRODUCTS	150
BRISTOL-MYERS SQUIBB.....	150
BUSINESS OVERVIEW.....	150
FINANCIALS	150
PRODUCTS	151
CIPLA, LTD.	151
BUSINESS OVERVIEW.....	151
FINANCIALS	151
PRODUCTS	151
CRUCCELL N.V.....	152
BUSINESS OVERVIEW.....	152
FINANCIALS	153
PRODUCTS	153

CUBIST PHARMACEUTICALS	154
BUSINESS OVERVIEW	154
FINANCIALS	154
PRODUCTS	155
GILEAD SCIENCES, INC.....	155
BUSINESS OVERVIEW.....	155
FINANCIALS	155
PRODUCTS	156
Other Products.....	157
GLAXOSMITHKLINE.....	158
BUSINESS OVERVIEW.....	158
FINANCIALS	158
PRODUCTS	159
HOLLY PHARMACEUTICALS	160
BUSINESS OVERVIEW.....	160
FINANCIALS	160
PRODUCTS	160
IPCA LABORATORIES.....	160
BUSINESS OVERVIEW.....	161
FINANCIALS	161
PRODUCTS.....	161
JOHNSON & JOHNSON	161
BUSINESS OVERVIEW.....	161
FINANCIALS	162
PRODUCTS	162
MANGALAM DRUGS & ORGANICS, LTD.	163
BUSINESS OVERVIEW.....	163
FINANCIALS	163
PRODUCTS	163
MERCK & CO.	164
BUSINESS OVERVIEW.....	164
FINANCIALS	164
PRODUCTS.....	165
NOVARTIS INTERNATIONAL AG.....	165
BUSINESS OVERVIEW.....	165
FINANCIALS	166
PRODUCTS	166
PFIZER.....	167
BUSINESS OVERVIEW.....	167
FINANCIALS	167
PRODUCTS.....	168
PIDI STANDARD	169
BUSINESS OVERVIEW.....	169
FINANCIAL	169

PRODUCTS	170
ROCHE	170
BUSINESS OVERVIEW	170
FINANCIALS	170
PRODUCTS	170
SANOFI-AVENTIS	171
SANOFI PASTEUR	171
BUSINESS OVERVIEW	171
FINANCIALS	172
PRODUCTS	173
SOLVAY PHARMACEUTICALS S.A.	173
BUSINESS OVERVIEW	174
FINANCIALS	174
PRODUCTS	175
VERTEX PHARMACEUTICALS	175
BUSINESS OVERVIEW	175
FINANCIALS	175
PRODUCTS	176
WYETH PHARMACEUTICALS (PFIZER, INC.)	176
BUSINESS OVERVIEW	176
FINANCIALS	177
PRODUCTS	177